In our study, in addition to the classical rearrangements, we detected the fusion BCOR-CCNB3, which defines a tumor subtype; the pathognomonic fusion NAB2-STAT6, which is more relevant in the latest WHO classification than previous versions; and the ETV6-NTRK3 fusion, which has approved drug treatments. This evidence concerns the gene CCNB3 and neoplasm.